139 related articles for article (PubMed ID: 21210141)
1. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
Wong D; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):161-2. PubMed ID: 21210141
[No Abstract] [Full Text] [Related]
2. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
Curtis LH; Hammill BG; Schulman KA; Cousins SW
Arch Ophthalmol; 2010 Oct; 128(10):1273-9. PubMed ID: 20937996
[TBL] [Abstract][Full Text] [Related]
3. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
Csaky K; Do DV
Am J Ophthalmol; 2009 Nov; 148(5):647-56. PubMed ID: 19712924
[TBL] [Abstract][Full Text] [Related]
4. Endophthalmitis after anti-VEGF injections.
Klein KS; Walsh MK; Hassan TS; Halperin LS; Castellarin AA; Roth D; Driscoll S; Prenner JL
Ophthalmology; 2009 Jun; 116(6):1225.e1. PubMed ID: 19486799
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
7. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
8. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
[TBL] [Abstract][Full Text] [Related]
9. [Non-response and change of anti-VEGF agent in exsudative age-related macular degeneration].
Manfreda I; Uhlig CE
Klin Monbl Augenheilkd; 2010 Aug; 227(8):657-8. PubMed ID: 20706974
[No Abstract] [Full Text] [Related]
10. The effect of image quality on retinal nerve fiber layer measurement in Stratus OCT.
Qiu KL; Zhang MZ
Am J Ophthalmol; 2011 Feb; 151(2):384; author reply 384-5. PubMed ID: 21251500
[No Abstract] [Full Text] [Related]
11. Treatment of exudative age-related macular degeneration: many factors to consider.
Olsen TW
Am J Ophthalmol; 2007 Aug; 144(2):281-3. PubMed ID: 17659955
[No Abstract] [Full Text] [Related]
12. [Treatment of neovascular age-related macular degeneration with bevacizumab].
Monzón Moreno A
Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
[No Abstract] [Full Text] [Related]
13. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
15. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
Ehlers JP; Spirn MJ; Shah CP; Fenton GL; Baker PS; Regillo CD; Ho AC
Ophthalmic Surg Lasers Imaging; 2010; 41(2):182-9. PubMed ID: 20307035
[TBL] [Abstract][Full Text] [Related]
17. [Intravitreal injection. Monitoring to avoid postoperative complications].
Meyer CH; Ziemssen F; Heimann H
Ophthalmologe; 2008 Feb; 105(2):143-55, 157. PubMed ID: 18256842
[TBL] [Abstract][Full Text] [Related]
18. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study.
Kemp A; Preen DB; Morlet N; Clark A; McAllister IL; Briffa T; Sanfilippo FM; Ng JQ; McKnight C; Reynolds W; Gilles MC
Retina; 2013 May; 33(5):920-7. PubMed ID: 23492942
[TBL] [Abstract][Full Text] [Related]
19. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
